Collagen type I production decreases with aging, leading to wrinkles and impaired skin function. Prostaglandin E2 (PGE2), a lipid-derived signaling molecule produced from arachidonic acid by cyclo-oxygenase, inhibits collagen production and induces matrix metallopeptidase 1 (MMP1) expression by fibroblasts in vitro. PGE2-induced collagen expression inhibition and MMP1 promotion are aging mechanisms. This study investigated the role of E-prostanoid 1 (EP1) in PGE2 signaling in normal human dermal fibroblasts (NHDFs). When EP1 expression was inhibited by EP1 small interfering RNA (siRNA), there were no significant changes in messenger RNA (mRNA) levels of collagen, type I, alpha 1 (COL1A1)/MMP1 between siRNA-transfected NHDFs and siRNAtransfected NHDFs with PGE2. This result showed that EP1 is a PGE2 receptor. Extracellular signalregulated kinase 1/2 (ERK1/2) phosphorylation after PGE2 treatment significantly increased by ~2.5 times. In addition, PGE2 treatment increased the intracellular Ca 2+ concentration in NHDFs. These results indicated that PGE2 is directly associated with EP1 pathway-regulated ERK1/2 and inositol trisphosphate (IP3) signaling in NHDFs.
skin squamous cell carcinoma, skin inflammatory conditions, such as sunburn, and aging skin [10, 16] . PGE2-mediated intracellular signal transduction depends on the binding of cells to one or more prostaglandin E receptors (E-prostanoid 1-4 [EP1-EP4]), which are coupled to different G-proteincoupled receptors (G-PCRs). Especially, EP1 is coupled to Gq protein alpha (Gαq), which activates phospholipase C (PLC), which, in turn, cleaves phosphatidylinositol 4,5-bisphosphate (PIP2), a membrane phospholipid, to generate second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses through the cytoplasm to bind to an open Ca 2+ channel of the endoplasmic reticulum (sarcoplasmic reticulum in muscle tissue), increasing cytoplasmic Ca 2+ . DAG activates protein kinase C (PKC), which subsequently activates the mitogen-activated protein kinase (MAPK) pathway via extracellular signal-regulated kinase (ERK) phosphorylation [17, 18] .
Many studies have extensively investigated COX2 and PGES1 induction in response to acute inflammation [10, [13] [14] [15] 19, 20] ; however, few studies have reported which receptors in dermal fibroblasts recognize PGE2 and affect fibroblasts. This study investigated the role of EP1 in PGE2 signaling in normal human dermal fibroblasts (NHDFs).
Results and Discussion

Viability of PGE2 in NHDFs
Before investigating the messenger RNA (mRNA) expression of dermal aging-associated proteins in NHDFs after PGE2 treatment, I first determined the noncytotoxic PGE2 concentration using a Cell Counting Kit-8 (CCK-8) assay. PGE2-induced NHDF apoptosis gradually increased with the PGE2 concentration. Cell viability after 100 μg/mL PGE2 treatment decreased by 25.3% compared to the control (Figs. 1A and 1B). In addition, phase contrast microscopy showed no significant differences in cell morphology after 50 μg/mL PGE2 treatment (Fig. 1C ). Therefore, I selected 50 μg/mL of PGE2 as the experimental condition for NHDFs in further experiments. 
Effects of PGE2 on mRNA expression-associated skin aging in NHDFs
Next, I assessed the effects of PGE2 on COL1A1 and MMP1 expression of NHDFs. PGE2 treatment reduced COL1A1 mRNA levels by ~79% and increased MMP1 mRNA levels by 4.4-fold (P < 0.05) ( Fig. 2A, B ). Li et al. (2015) have shown that PGE2 is largely responsible for inhibiting procollagen expression in human skin organ culture [10] . The authors reported that increased COX2 expression in the aging dermis increases PGE2 production and consequently decreases collagen production. These results were consistent with my results, and I further confirmed that PGE2 treatment increasesMMP1 expression. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of commonly used drugs, such as aspirin, ibuprofen, diclofenac, and indomethacin, which reduce COX1 and COX2 activity, thereby decreasing PGE2 production [21] . Topical NSAIDs can decrease PGE2 production in human skin. These results provide a rationale for investigating the beneficial effects of NSAIDs for collagen deficiency or MMP1 excess in aging skin. With regard to PGE2-associated signaling transduction, PGE2 activity is exerted via four receptors: EP1-EP4 [22] [23] [24] . Skeletal muscles have muscle-specific stem cells (MuSCs) capable of tissue regeneration throughout life. PGE2, an inflammatory cytokine, targets MuSCs via EP4, leading to MuSC proliferation and regeneration [20] . With regard to fibrosis and keloids, recent studies have shown that EP2 transduces PGE2 signaling and results in collagen synthesis downregulation [25] [26] [27] [28] . However, there are no studies on what PGE2 receptors are present in NHDFs. Therefore, to investigate PGE2 targets in NHDFs, the mRNA expression of EP1-EP4 were evaluated. First, I confirmed the downregulation of EP1 and EP4 gene transcription by PGE2 treatment (Fig. 3A, D) . The mRNA expression of EP2 and EP3 was also evaluated. In contrast to EP1/4, I found no significant changes in EP2/3 expression after PGE2 treatment ( Fig. 3B , C). PGE2 treatment was expected to increase the expression of specific receptors between EP1-EP4 in NHDFs; however, I observed decreased EP1/4 expression, as shown in Figs. 3A and 3D. Studies have shown that chronic insulin treatment decreases insulin receptor expression in adipose-derived insulin-producing cells [29] , and a high insulin dose can induce alterations in insulin action, which might account, in part, for insulininduced desensitization. PGE2 is a major eicosanoid product of fibroblasts and regulates fibroblast function in an autocrine fashion [30, 31] . I believe that a similar result is observed in the decrease in EP1 expression after high-dose PGE2 treatment for 24 h. 
EP1 siRNA treatment hides PGE2 effects
To determine the role of EP1 in regulating the PGE2 reaction in NHDFs, I performed small interfering RNA (siRNA)-mediated EP1 knockdown experiments in NHDFs. Experiments were also performed by inhibiting the function of EP1-EP4 using antagonists or neutralizing antibodies. In the case of the receptor antagonist, I observed that the inhibition efficiency of each antagonist against PGE2 binding by EP1-EP4 was not constant. In the case of neutralizing antibodies, I found no commercialized antibodies that responded to EP1-EP4, so I applied the siRNA system to this study. When EP1 siRNA inhibited EP1 expression ( Supplementary Fig. 1 ), I observed no significant change in mRNA expression of COL1A1/MMP1 between siRNA-transfected NHDFs and siRNA-transfected NHDFs with PGE2 ( Fig. 4) . In contrast, after PGE2 treatment in EP2-EP4 knockdown conditions, mRNA expression of COL1A1 decreased and MMP1 expression increased ( Supplementary Fig. 2 ). These results showed that EP1 is a receptor for PGE2 in NHDFs. 
PGE2-mediated intracellular signaling of EP1
EP receptors transmit signals by mobilization of intracellular Ca 2+ and MAPK (EP1), increased cyclic adenosine monophosphate (cAMP; EP2 and EP4), or decreased cAMP (EP3). Because of these distinct signaling pathways, pleiotropic (or even antagonistic) responses to PGE2 might be seen in different cells, depending on the profile of the EP receptors expressed. Especially, EP1 signals through the G-PCR-mediated phosphatidylinositol-specific phospholipase C-β (PI-PLCβ) signaling pathway.
PLCβ activation hydrolyzes PI 4,5-biphosphate into two second messengers, IP3 (which activates cytoplasmic Ca 2+ levels via movement from endoplasmic reticulum stores, leading to activation of Ca 2+ signaling pathways) and DAG (which triggers PKC). Subsequently, PKC triggers the MAPK pathway via Raf-1/ERK activation [17, 18] . To confirm whether PGE2 binds to EP1 and affects intracellular signaling, I conducted time-course ERK1/2 phosphorylation. Results showed that ERK1/2 phosphorylation after 1, 2, and 4 h of PGE2 treatment significantly increased by ~2.5 times compared to the control (Fig. 5A, B ). However, I found no significant difference in p-ERK1/2 expression between control and stimulated conditions after >=4 h of PGE2 treatment. I also examined the effect of PGE2 treatment on intracellular Ca 2+ levels using Fura-2acetoxymethyl (Fura-2AM), a membrane-penetrating radiometric fluorescent indicator used for Ca 2+ imaging by fluorescence. Inside the cells, the acetoxymethyl groups in Fura-2AM are removed by intracellular esterases, generating Fura-2, the pentacarboxylate Ca 2+ indicator. The ratio of emissions at wavelengths of 340 and 380 nm is directly correlated to the cytoplasmic Ca 2+ concentration [32] [33] [34] . Exposure of NHDFs to 50 μg/ml of PGE2 triggered a time-dependent increase in the intracellular Ca 2+ concentration after 3 and 6 h of treatment (Fig. 5C ). Fig. 5 shows how PGE2 induces intracellular signaling of EP1. Studies have reported EP1 agonists, such as ONO-8103, ONO-8359, GSK269984A, and GSK345931A, as EP1 inhibitors [35] [36] [37] [38] . Each inhibitor alleviates bladder pain [35] or suppresses acid-derived heartburn symptoms [36] and inflammatory pain [38] . Future studies are required in order to identify these agonists as potential anti-aging materials.
In summary, PGE2 decreases collagen type I expression and increases MMP1 expression [10] ; inhibition of collagen expression and MMP1 promotion by PGE2 are skin aging mechanisms. PGE2 also decreases EP1 expression in NHDFs. However, when treated under conditions of EP1 knockdown in NHDFs, PGE2 does not affect collagen type I and MMP1 expression. In addition, PGE2 bound to EP1 transmits the signal through intracellular Ca 2+ and ERK pathway. NHDFs are used as a model to evaluate transcriptional changes in PGE2 treatment, demonstrating that EP1 plays an important role in PGE2 signaling. These results suggest that PGE2 is directly associated with the EP1 receptor pathway-regulated ERK1/2 and IP3 signaling in NHDFs. This study provided a rationale for the beneficial effects of blocking EP1-PGE2 interaction on collagen deficiency in aging skin (Fig. 6 ). Figure 6 . Schematic model for the mechanism contributing to beneficial effects of blocking EP1-PGE2 interaction in NHDFs. ↑, increase; ↓, decrease. EP, E-prostanoid; PGE2, prostaglandin E2; NHDF, normal human dermal fibroblast.
Materials and Methods
Cell culture of NHDFs
NHDFs (Lonza, Switzerland) were cultured in Dulbecco's Modified Eagle Medium (DMEM; Welgene, Korea) containing 10% fetal bovine serum (FBS; Equitech-Bio, USA), 100 U/mL of penicillin, and 100 μg/mL of streptomycin in a 5% CO2 humidified incubator at 37°C. The NHDFs were used for experiments at passages 3-12.
Effects of PGE2 on mRNA expression-associated skin aging in NHDFs
To assess the effects of PGE2 on COL1A1 and MMP1 expression of NHDFs, NHDFs were cultured in serum-free DMEM for 24 h in the presence of PGE2 or dimethyl sulfoxide (DMSO) (Sigma-Aldrich Corporation, St. Louis, MO, USA) as the control. COL1A1 and MMP1 expression was examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR).
In vitro cell viability assay
The cell viability of NHDFs was determined using a CCK-8 assay (Dojindo, Japan). Briefly, NHDFs were seeded in 96-well tissue culture plates at a density of 2 × 10 3 cells per well, treated with 10 μL of CCK-8 solution in 90 μL of phenol red-free DMEM (Welgene), and incubated for 1 h at 37°C. Absorbance was measured at a wavelength of 450 nm using an Epoch microplate spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA).
Real-time qRT-PCR
Total RNA was extracted from NHDFs using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA), and the RNA concentration was quantified using an Epoch Take3 microvolume spectrophotometer (BioTek Instruments). Then, 2 μg of RNA was reverse-transcribed into complementary DNA (cDNA) using a Superior Script III master mix (Enzynomix, Korea), and reverse transcription was stopped by adding Tris-ethylenediaminetetraacetic acid (EDTA) buffer (pH 8.0) to 100 μL of cDNA solution. Table 1 presents the gene identification numbers for the TaqMan Gene Expression assay used in realtime qRT-PCR analysis. Human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to normalize variation in cDNA quantities from different samples. 
EP1 siRNA transfection
After they reached ~70%-80% confluency, NHDFs were transfected with an EP1-specific silencer ® select siRNA (S194725; Thermo Fisher Scientific) or a negative control siRNA (Thermo Fisher Scientific). Transfection was performed using Lipofectamine ® RNAiMAX TM (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, a mixture of human EP1 siRNA and Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 27 October 2019 doi:10.20944/preprints201910.0305.v1
Lipofectamine ® RNAiMAX TM was diluted in 500 μL of antibiotic-free Opti-MEM TM (Invitrogen). After slightly agitating the mixture for 20 min at room temperature, NHDFs were incubated in the mixture for 6 h at 37°C. Then, the medium was removed and exchanged with DMEM containing 10% FBS. Table 2 presents siRNA identification numbers for the gene knockdown assay. Table 2 . siRNA Name and siRNA ID Number in Knockdown Analysis.
Symbol
ID Number
EP1 siRNA S194725 EP2 siRNA S11448 EP3 siRNA S11451 EP4 siRNA S11454 Control siRNA D-001810-01-05
Immunoblotting analysis
NHDFs were lysed on ice for 2 h with radioimmunoprecipitation assay (RIPA) lysis buffer (Merck Millipore, Burlington, MA, USA) with a protease/phosphatase inhibitor cocktail (Merck Millipore). After incubation, NHDF lysates were centrifuged at 12,000 rpm for 15 min at 4°C, and the supernatants were collected into new EP-tubes. For immunoblotting analysis, 20 μg of protein was separated on 4%-12% gradient Bis-Tris gels before transfer to polyvinylidene difluoride (PVDF) membranes (Thermo Fisher Scientific). The PVDF membranes then were blocked by incubation in Tris-buffered saline with Tween-20 (TBST) buffer containing 1% bovine serum albumin (BSA; Sigma-Aldrich) for 1 h at room temperature and incubated overnight at 4°C with the GAPDH primary antibody (1:1,000; Santa Cruz Biotechnology, Dallas, TX, USA), ERK1/2 primary antibody, or the phosphor-ERK1/2 primary antibody (1:1,000; Abcam, UK) in TBST containing 1% BSA. Blots were washed thrice with TBST and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:3,000; Bio-Rad Laboratories, Inc., Hercules, CA, USA) for 1.5 h at room temperature. Finally, the blots were developed using Clarity Western ECL blotting substrate (Bio-Rad Laboratories) according to the manufacturer's instructions.
Ca 2+ imaging
Fura-2-AM (Abcam) is a membrane-penetrating derivative of the radiometric Ca 2+ indicator used to measure cytoplasmic Ca 2+ concentrations by fluorescence. Ca 2+ imaging of Fura-2AM-loaded NHDFs was performed using a CELENA ® S digital imaging fluorescence microscope (Logos Biosystems, Korea) with excitation at a wavelength of 405 nm and fluorescence emission measurements at a wavelength of 519 nm. NHDFs on the confocal dish (SPL, Korea) were loaded for 30 min in the dark at room temperature in Hanks' Balanced Salt Solution (HBSS) (Welgene) containing 2 μM Fura-2AM. The dish was then rinsed thrice with HBSS. Next, the NHDFs were again incubated for 30 min at 37°C. Finally, they were washed with prewarmed HBSS, and the live NHDFs were imaged using a fluorescence microscope.
Statistical analysis
Statistical analysis of data was performed using one-way analysis of variance (ANOVA). Results were presented as the mean ± standard deviation (SD) of three or more independent experiments. P < 0.05 was considered statistically significant.
